Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 09 February 2018 | By Michael Mezher
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) on Friday recommended that women taking Gedeon Richter's Esmya (ulipristal) to treat uterine fibroids undergo regular liver testing while the agency investigates reports of liver failure related to the drug.
PRAC also recommended that no new patients begin taking Esmya, and that patients who have already completed a course of the drug wait until the agency has completed its safety review before beginning a new course.
"All women taking Esmya should have a liver function test at least once a month during treatment," EMA writes, adding that if liver enzyme levels are more than twice the upper limit for normal levels the patient's physician should discontinue treatment immediately and monitor the patient.
EMA is also advising patients to be on the lookout for signs of liver injury, including nausea, vomiting, stomach pain, lack of appetite or yellowing of the eyes or skin while taking the drug.
EMA first launched its safety review into Esmya in December 2017 after PRAC concluded that the reports of liver injury could be caused by the drug, which was first authorized in the EU in 2012. The drug is also marketed by Allergan as Fibristal in Canada, and in October 2017, Allergan announced the US Food and Drug Administration (FDA) had accepted its new drug application (NDA) for the drug for review.
Following news of EMA's safety review in December, Gedeon Richter denied a link between the drug and liver damage. At the time, a spokesperson for the company Zsuzsa Beke told Reuters that "we consider that there is no demonstrable link between liver damage and treatment with Esmya."
EMA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.